drugset / Trial / NCT06963216
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
Timeline
- Start
- 2026-06
- Primary completion
- 2026-06-10
- Completion
- 2026-06-10
Outcome
Outcome not reported
Stopped: “Study was discontinued for non-safety reasons and the rapidly evolving treatment landscape for AL amyloidosis.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coagadex | Protein / enzyme biologic | 40 iu/kg | — |